TPAG organizes Thalassemia & SCD prevention discussion
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The appointment is effective from May 01, 2023 for five years
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated